Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
α-Actinin 3(ACTN3) is a structural protein of the Z-line of skeletal muscle fast muscle fibers that maintains the orderly alignment and normal contraction of muscle fibers by binding to actin in thin filaments. The ACTN3 gene is located at 11q13.1 and encodes α-Auxiliary 3 protein. There are four forms of existence in the α-actin family. ACTN1 and 4 are present in non-striated muscles and act as anchors for cell scaffolds. ACTN2 and 3 are present in skeletal muscle fibers, and ACTN2 is present in all types of skeletal muscle fibers. While ACTN3 is present only in fast muscle fibers, fast muscle fibers produce the shrinkage required for explosiveness. Recent studies have shown that ACTN3 polymorphisms may affect other motor-related variables, including training adaptation, post-exercise recovery, and exercise-related impairment.
Figure 1. A summary of the potential wider implications of ACTN3 genotype on outcomes from exercise. (Craig Pickring., et al. 2017)
ACTN3 Gene Polymorphism
Currently, studies on the ACTN3 gene polymorphism are focused on the exon 16 R577X polymorphism. The C-T polymorphism at this locus results in a change in the amino acid encoding position 577 from arginine (577R) to termination coding (577X), and when terminated, α-actinin-3 is deleted. The frequency of occurrence of the 577X allele varies from race to race, such as less than 10% in some African populations and 50% in Eurasian populations. The XX genotype of ACTN3 R577X is characterized by a complete absence of ACTN3, which is estimated to be 1.5 billion people worldwide. Deletion of ACTN3 does not cause any disease because ACTN2, which is 80% identical in structure to ACTN3, compensates for up-regulated expression. However, the expression of ACTN3 has a special effect on fast muscle fibers. Beginning with the Australian scholar Yang et al., many scholars and researchers in the field of sports science are concerned about whether the presence or absence of ACTN3 in the fast muscle fibers of the human body affects the quality of exercise and performance. In particular, the explosive quality, that is, whether the ACTN3 gene R577X polymorphism is associated with explosive quality.
ACTN3 and Athletic Ability
The earliest research on the association between ACTN3 R577X polymorphism and athletic performance of elite athletes was conducted with Caucasian athletes as subjects. As a result, it was found that the absence of α-actinin-3 (XX genotype) was significantly higher in the elite endurance athletes than in the healthy controls. In subsequent studies, some studies showed that the X allele or XX genotype was associated with outstanding endurance quality, while others did not. In contrast, the ACTN3 R577X polymorphism is more consistent with the findings associated with superior explosiveness. The study found that the frequency of XX genotype distribution of ACTN3R577X polymorphism was lower in elite explosive quality athletes than in elite endurance athletes and control populations. Since then, there have been many repetitive studies that have yielded significant results in different elite athletes (such as sprinters, long jumps, high jumps, throws) and weightlifters. Some studies have shown that the ACTN3 577XX genotype is distributed at a frequency of excellent explosive quality athletes and excellent endurance athletes, but there is no significant difference between the control population. Inconsistent findings may be related to sample size and ethnic differences.
The distribution frequency of ACTN3 577XX is also different among explosive athletes with different levels of exercise. If studies have found that the ACTN3 577XX genotype distribution frequency of short-distance swimmers in Taiwan's Olympic level is significantly lower than that of non-Olympic athletes. The ACTN3 R577X polymorphism is sometimes combined with other genetic polymorphisms to explore the preferred multi-gene combination that affects the explosive quality.
To further understand the effects of the ACTN3 R577X polymorphism on physiological and metabolic functions, the researchers established a mouse model of ACTN3 knockout. Compared with wild-type mice, ACTN3 knockout mice had a faster diameter of the fast muscle fibers, a decrease in muscle mass, a marked decrease in paw grip, and a marked increase in endurance. It can be seen that the absence of ACTN3 directly leads to a tendency of mouse muscle properties to transform into slow muscle fiber properties. Through anatomical analysis, it was found that the activity of anaerobic metabolic enzymes in the fast muscle fibers of mice decreased, and the activity of aerobic metabolic enzymes increased, but the distribution of muscle fiber types did not change. The activity of lactate dehydrogenase in the oxygen metabolism pathway is lowered, resulting in the insufficient conversion of pyruvic acid to lactic acid. A part of the aerobic metabolic pathway enters the tricarboxylic acid cycle; on the other hand, the activity of citrate synthase and succinate dehydrogenase in the aerobic metabolic pathway is increased, which further promotes the entry of pyruvic acid into the aerobic metabolism pathway. Then it will cause a decrease in anaerobic metabolism and an increase in aerobic capacity. A related study of ACTN3 knockout mice can roughly explain why the ACTN3 XX genotype has poorer burst quality and better endurance quality.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.